We are conducting discovery and pre-clinical research into a range of other conditions and using other engineered forms of Coversin. Current programs include :
- The use of an engineered, targeted version of Coversin for the treatment of other diseases such as Myasthenia Gravis where Coversin has been engineered to target the neuromuscular junction
- Rheumatoid arthritis, where Akari recently announced pre-clinical data
- Trauma where Akari has an ongoing program
